Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report) have been given a consensus recommendation of “Hold” by the five brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $67.67.
Several analysts have issued reports on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th.
Prestige Consumer Healthcare Stock Up 1.9%
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. During the same quarter in the prior year, the business posted $0.90 EPS. The company’s revenue for the quarter was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, equities research analysts predict that Prestige Consumer Healthcare will post 4.56 earnings per share for the current fiscal year.
Institutional Trading of Prestige Consumer Healthcare
Several institutional investors have recently added to or reduced their stakes in PBH. Barrow Hanley Mewhinney & Strauss LLC bought a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth about $30,000. Versant Capital Management Inc lifted its holdings in Prestige Consumer Healthcare by 47.9% in the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock worth $34,000 after acquiring an additional 235 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after acquiring an additional 236 shares during the last quarter. Cornerstone Planning Group LLC acquired a new position in Prestige Consumer Healthcare in the first quarter valued at approximately $44,000. Finally, Hantz Financial Services Inc. boosted its stake in Prestige Consumer Healthcare by 71.6% in the fourth quarter. Hantz Financial Services Inc. now owns 1,170 shares of the company’s stock valued at $72,000 after acquiring an additional 488 shares during the period. Institutional investors own 99.95% of the company’s stock.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc (NYSE: PBH) develops, markets and distributes over-the-counter health care products and household consumer products. Its portfolio includes branded treatments for eye care, gastrointestinal health, women’s health, oral care, respiratory conditions, pain relief and skin care, along with products for lice treatment and motion sickness.
The company’s brands include Clear Eyes, Dramamine, Monistat, Summer’s Eve, Compound W, Chloraseptic, Luden’s, BC, Goody’s, Nix and Hydralyte, among others.
Featured Stories
- Five stocks we like better than Prestige Consumer Healthcare
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
